The University of Oxford has published data from the Phase II trial of its Covid-19 vaccine, ChAdOx1 nCov-2019, showing it had similar neutralising antibody titres and T cell responses across all age groups and people with co-morbidities.
The study results, which were published in the Lancet, also found that ChAdOx1 nCov-2019 was better tolerated in older adults aged 56 and over than in younger adults.
Go deeper with GlobalData
These Phase II results are consistent with the findings of University of Oxford’s Phase I study.
Investigator at the Oxford Vaccine Group and consultant physician said Dr Maheshi Ramasamy said in a release: “Older adults are a priority group for Covid-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses.
“We were pleased to see that our vaccine was not only well tolerated in older adults; it also stimulated similar immune responses to those seen in younger volunteers. The next step will be to see if this translates into protection from the disease itself.”
The University of Oxford is collaborating with AstraZeneca on the development of ChAdOx1 nCov-2019. The vaccine is currently being studied in a Phase III trial; results are expected to be announced in the next few weeks.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
